Want to see KR:183490 full AI Analyst Report?
Top Page
Enzychem Lifesciences Corp.
(183490)
Select Model
Select Model
Rating:49Neutral
Price Target:
₩985.00
Action:N/A
Date:10/28/26
The score is held down primarily by ongoing losses and worsening cash burn despite a much improved, low-leverage balance sheet. Technical indicators also lean weak (below the 200-day average with low RSI/stochastic), while valuation support is limited because the company is loss-making and no dividend yield is available.
Positive Factors
Conservative leverage
Very low leverage and sizable equity provide financial flexibility while the company works through ongoing losses. A conservative capital structure can reduce financing pressure, preserve capacity to fund operations, and offer greater resilience over the next several quarters.
Negative Factors
Persistent unprofitability
Persistent operating and net losses show that the business has not yet demonstrated a durable path to profitability. Deeply negative margins weaken internal funding capacity, limit reinvestment flexibility, and make future earnings power dependent on a meaningful operating improvement.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative leverage
Very low leverage and sizable equity provide financial flexibility while the company works through ongoing losses. A conservative capital structure can reduce financing pressure, preserve capacity to fund operations, and offer greater resilience over the next several quarters.
Read all positive factors
Enzychem Lifesciences Corp. (183490) vs. SPDR S&P 500 ETF (SPY)
Market Cap
₩76.86B
Dividend YieldN/A
Average Volume (3M)0.00
Price to Earnings (P/E)―
Beta (1Y)-0.14
Revenue Growth-5.10%
EPS Growth19.68%
CountryKR
EmployeesN/A
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-233.30
Shares Outstanding84,640,236
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.43
Price to Book (P/B)0.94
Price to Sales (P/S)1.91
P/FCF Ratio-10.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Enzychem Lifesciences Corp. Business Overview & Revenue Model
Company Description
Enzychem Lifesciences Corporation specializes in the creation and manufacturing of active pharmaceutical ingredients (APIs) and specialized nutritional products. Its operations also extend to the production of a diverse range of animal health prod...
Enzychem Lifesciences Corp. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
72
Positive
Cash Flow
24
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 67.75B | 77.38B | 76.04B | 26.64B | 22.98B |
| Gross Profit | 3.38B | 4.31B | 4.35B | 2.42B | 286.72M |
| EBITDA | -14.90B | -18.39B | -5.75B | -13.16B | -17.89B |
| Net Income | -18.13B | -22.11B | -9.33B | -25.09B | -27.86B |
Balance Sheet | |||||
| Total Assets | 148.59B | 181.74B | 211.55B | 247.55B | 133.08B |
| Cash, Cash Equivalents and Short-Term Investments | 92.82B | 117.07B | 137.35B | 192.86B | 94.59B |
| Total Debt | 4.84B | 4.88B | 5.66B | 37.78B | 51.98B |
| Total Liabilities | 9.83B | 20.26B | 16.92B | 45.81B | 58.42B |
| Stockholders Equity | 137.54B | 160.35B | 193.52B | 201.74B | 74.66B |
Cash Flow | |||||
| Free Cash Flow | -11.79B | -1.06B | -12.56B | -22.33B | -24.47B |
| Operating Cash Flow | -11.01B | -573.93M | -10.26B | -14.32B | -18.59B |
| Investing Cash Flow | 11.93B | 7.36B | 53.56B | -109.23B | -9.73B |
| Financing Cash Flow | -3.34B | -12.14B | -35.50B | 128.50B | 29.26B |
Enzychem Lifesciences Corp. Technical Analysis
Negative
―
Price Trends
990.00
Neutral
990.00
Neutral
1041.30
Negative
Market Momentum
>-0.01
Negative
37.46
Neutral
15.38
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KR:183490, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 990.00, equal to the 50-day MA of 990.00, and equal to the 200-day MA of 1041.30, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 37.46 is Neutral, neither overbought nor oversold. The STOCH value of 15.38 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KR:183490.
Enzychem Lifesciences Corp. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | ₩1.16T | 5.95 | ― | 0.59% | 9.87% | 160.28% | |
60 Neutral | ₩397.78B | 8.87 | ― | 1.59% | -0.65% | ― | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
54 Neutral | ₩1.59T | 130.86 | ― | 0.42% | 13.88% | 29.24% | |
49 Neutral | ₩76.86B | -8.16 | ― | ― | -5.10% | 19.68% | |
46 Neutral | ₩322.72B | -55.36 | ― | 2.07% | 15.38% | ― | |
40 Underperform | ₩40.05B | -0.23 | ― | ― | 26.13% | 58.75% |
* General Sector Average
KR:183490
Enzychem Lifesciences Corp.
990.00
-27.00
-2.65%
KR:003060
Aprogen Biologics
1,335.00
-6,945.00
-83.88%
KR:068760
Celltrion Pharm Inc.
36,650.00
-25,696.91
-41.22%
KR:069620
Daewoong Pharmaceutical Co., Ltd.
101,100.00
-37,819.86
-27.22%
KR:170900
Dong-A ST Co., Ltd.
33,850.00
-12,035.84
-26.23%
KR:249420
Ildong Pharmaceutical Co., Ltd.
12,580.00
-10,764.63
-46.11%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.